Keywords: Daiichi Sankyo, USA, FDA, Benicar, Olmesartan, Blood pressure, Pediatric, Management

Daiichi Sankyo gains US FDA approval of Benicar to treat high BP in children and adolescent; names new VP medical affairs

Article | 12 February 2010

Print This

The US Food and Drug Administration has approved Japanese drug major Daiichi Sankyo’s antihypertensive Benicar (olmesartan medoxomil) for use ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in